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Abstract Elafin (elastase-specific inhibitor) is a low molecular
weight inhibitor of neutrophil elastase which is secreted in the
lung. Using synthetic peptides corresponding to full-length elafin
(H2N-1AVT.....95Q-OH), the NH2-terminal domain (H2N-
1AVT.....50K-OH) and the COOH-terminal domain (H2N-
51PGS.....95Q-OH), we demonstrate that elafin’s anti-elastase
activity resides exclusively in the COOH-terminus. Several
characteristics of elafin suggest potential anti-microbial activity.
The anti-microbial activity of elafin, and of its two structural
domains, was tested against the respiratory pathogensPseudo-
monas aeruginosa and Staphylococcus aureus. Elafin killed both
bacteria efficiently, with 93% killing of P. aeruginosa by 2.5 WM
elafin and 48% killing of S. aureus by 25 WM elafin. For both
organisms, full-length elafin was required to optimise bacterial
killing. These findings represent the first demonstration of co-
existent anti-proteolytic and anti-microbial functions for elafin.
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1. Introduction
As part of the immediate defence against bacterial patho-
gens, the lung is equipped with a number of endogenous anti-
microbial peptides, including defensins, secretory leucocyte
protease inhibitor (SLPI), lysozyme and lactoferrin [1^6]. In
addition, bacteria stimulate the recruitment and activation of
neutrophils, resulting in engulfment of organisms and ulti-
mately their destruction by oxidants or proteolytic enzymes
such as human neutrophil elastase (HNE) [7]. Natural inhib-
itors of HNE in the lung are thought to play a critical role in
neutralising HNE liberated extracellularly, thus circumventing
proteolytic damage to the host [8].
Ela¢n (also known as ela¢n-speci¢c inhibitor (ESI) or skin
anti-leucoprotease (SKALP)) is a low molecular weight (9.9
kDa) inhibitor of HNE and proteinase 3, which is secreted in
the respiratory tract [9,10]. Along with K1-protease inhibitor
(K1-PI) [8] and SLPI [11], ela¢n comprises an integral part of
the ‘anti-elastase shield’ in the lung [12].
Several features suggest an additional anti-microbial func-
tion for ela¢n. In particular, ela¢n is highly cationic, it is
expressed selectively in the lung, the skin and at mucosal
surfaces and SLPI (which has 42% sequence homology with
ela¢n) has anti-microbial activity [5,13^17].
In this study, we describe an investigation of the anti-micro-
bial activity of ela¢n against Pseudomonas aeruginosa and
Staphylococcus aureus, two important pulmonary pathogens
with a particular propensity to antibiotic resistance [18^23].
2. Materials and methods
2.1. Proteins
Ela¢n peptides were produced synthetically in accordance with the
derivation of amino acids from the established gene sequence [13] and
were supplied by Albachem (Edinburgh, UK), using standardised
protocols described elsewhere [24]. Three peptides were provided,
namely full-length ela¢n (H2N-1AVT.....95Q-OH), the NH2-terminus
domain (H2N-1AVT.....50K-OH) and the COOH-terminus domain
(H2N-51PGS.....95Q-OH). The terminal amino acid of the NH2 do-
main and the ¢rst amino acid of the COOH domain were determined
by analysis of the established crystal structure of a 57 amino acid
fragment of ela¢n (H2N-39AQE.....95Q-OH) [17], in conjunction with
the established sequence of human SLPI, which has 42% sequence
homology with ela¢n [13^15,25]. The molecular weights of ela¢n moi-
eties, determined by mass spectrometry (Albachem, Edinburgh, UK)
were 9925 Da for full-length ela¢n, 5172 Da for the NH2-terminal
domain and 4776 Da for the COOH-terminal domain.
Human serum albumin (HSA) was purchased from Sigma Chem-
icals (St. Louis, MO, USA). Recombinant human SLPI was pur-
chased from R and D Systems (Minneapolis, MN, USA). Lyophilised
preparations of ela¢n, SLPI and HSA were all reconstituted in 0.01 M
K2HPO4/KH2PO4, pH 7.4 (phosphate bu¡er).
2.2. Bacteria
PAO1, a clinical strain and well-characterised type strain of P.
aeruginosa, and C1705, a clinical strain of S. aureus, were available
in-house [20,24].
2.3. HNE activity assay
The HNE activity assay has been described in detail elsewhere [26].
Brie£y, serial dilutions of test inhibitor were added to 300 ng of
puri¢ed HNE (Elastin Products, Owensville, MO, USA). All dilutions
were performed in Tris 50 mM, Triton 0.1%, sodium chloride 0.5 M,
pH 8.0. The samples were incubated for 15 min at 37‡C before addi-
tion of the chromogenic substrate N-methoxysuccinyl-Ala-Ala-Pro-
Val-p-nitroanilide (Sigma). In positive controls, bu¡er replaced test
inhibitor. The change in absorbance, measured spectrophotometri-
cally at 405 nm (MR5000 Plate Reader, Dynatech, Dynex, Billing-
hurst, UK), was expressed as a function of time. The inhibitory ca-
pacity of test inhibitors was derived by extrapolation to the ordinate
of curves obtained by plotting the HNE activity against the concen-
tration of inhibitor added, as described elsewhere [27].
2.4. Assay of microbial activity
Bacteria were grown initially as colonies on Columbia agar (Uni-
path, Basingstoke, UK) and, then, in 10 ml tryptone soya broth (TSB)
(Unipath) overnight at 37‡C in an orbital shaker (Gallenkamp, Fisher
Scienti¢c, Loughborough, UK) at 200 rev/min. 100 Wl of the bacterial
culture was resuspended in 10 ml fresh TSB and incubated for 3 h at
37‡C with rotation, corresponding to a point compatible with loga-
rithmic growth for both PAO1 and C1705. The resulting suspension
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was centrifuged at 4500 rpm for 20 min at room temperature (Bio-
fuge, Heraeus Instruments, Kendro, Bishops Stortford, UK), the
supernatant discarded and replaced with 10 ml phosphate bu¡er
and then resuspended. This process was repeated once. The quantity
of viable bacteria was calculated from pre-constructed growth curves
and dilutions made in phosphate bu¡er to give an estimated count of
5U104 viable colonies per ml.
In experiments using puri¢ed ela¢n, HSA or SLPI, 30 Wl aliquots of
the bacterial suspension were added to 90 Wl aliquots of test sub-
stance, each diluted in phosphate bu¡er to give ¢nal concentrations
of 1, 2.5, 10 or 25 WM of the test substance. In positive controls, 90 Wl
of phosphate bu¡er replaced the test solution and in negative controls,
30 Wl of phosphate bu¡er replaced the bacterial suspension.
The test bacterial suspension mix was incubated for 2 h at 37‡C.
Appropriate dilutions were made in phosphate bu¡er and 100 Wl
aliquots plated out on Columbia agar. Colonies were counted after
incubation of the plates for 16 h at 37‡C.
2.5. Statistics
Data pertaining to S. aureus were normally distributed and com-
parisons between test substances and controls were performed using
the paired t-test. Data pertaining to P. aeruginosa were not normally
distributed and comparisons between test substances and controls
were performed using the Wilcoxon signed rank test. Statistical sig-
ni¢cance was regarded as P6 0.05.
3. Results
3.1. Anti-elastase activity of ela¢n moieties
All three peptides (full-length ela¢n, the NH2-terminal do-
main and the COOH-terminal domain) were tested for anti-
HNE activity (Fig. 1). No anti-HNE activity was detected in
the NH2-terminal domain. In contrast, the COOH-terminal
domain and the full-length molecule were found to have an
identical anti-HNE activity, indicating that ela¢n’s anti-elas-
tase activity resides exclusively in the COOH-terminal do-
main.
3.2. Anti-microbial activity of ela¢n
Full-length ela¢n resulted in a signi¢cant killing of PAO1 at
all doses tested (1^25 WM) (Fig. 2). The maximum e¡ect was
observed at 2.5 WM, at which 93% of PAO1 was killed, rela-
tive to PAO1 grown in phosphate bu¡er alone. At 1 and
2.5 WM, the contributions of the NH2-terminus and COOH-
terminus were approximately additive, but at higher doses, the
predominant anti-microbial e¡ect resided in the NH2-terminal
domain. The anti-microbial e¡ect of full-length ela¢n against
Fig. 1. Anti-elastase activity of full-length ela¢n, NH2-terminal do-
main ela¢n and COOH-terminal domain ela¢n. Known quantities
of test inhibitor were added to 300 ng HNE. All dilutions were per-
formed in Tris 50 mM, Triton 0.1%, sodium chloride 0.5 M, pH
8.0. Chromogenic substrate (N-methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide) was added and the change in absorbance at 405 nm
was measured as a function of time. The molecular weights of full-
length ela¢n, NH2-terminal domain ela¢n, COOH-terminal domain
ela¢n and HNE are 9.9, 5.2, 4.8 and 30 kDa, respectively. Results
are expressed as a percentage of the HNE activity when incubated
with bu¡er alone.
Fig. 2. Anti-microbial e¡ect of ela¢n moieties against P. aeruginosa
(PAO1) and S. aureus (C1705), expressed as a percentage of the col-
ony count in phosphate bu¡er alone (control). In (a), results repre-
sent medians (n = 8 for concentrations of 2.5^25 WM; n = 4 at 1 WM).
In (b), results represent means (n = 5). * = P6 0.05, ** = P6 0.01,
*** = P6 0.001.
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S. aureus (C1705) was dose-dependent and was signi¢cant
over a dose range of 2.5^25 WM (Fig. 2). At 25 WM, 48%
killing of C1705 was achieved. The NH2-terminus showed a
signi¢cant anti-microbial activity only at 25 WM and the
COOH-terminus only at 10 WM. To ensure that the e¡ects
observed were not attributable to a non-speci¢c peptide e¡ect,
the e¡ects of full-length ela¢n, the NH2-terminal domain and
the COOH-terminal domain against PAO1 and C1705 were
also compared with a control protein (HSA) (Fig. 3). For full-
length ela¢n, the maximal activity was described at 2.5 WM
against PAO1 (81% killing) and at 25 WM against C1705 (63%
killing) (Fig. 3), closely in keeping with the ¢ndings when the
e¡ect of full-length ela¢n was compared with that of phos-
phate bu¡er alone (Fig. 2). The dose-response curves gener-
ated for both NH2-terminal domain ela¢n and COOH-termi-
nal domain ela¢n against PAO1 and C1705 also closely
paralleled those obtained when survival was expressed relative
to PO4 bu¡er instead of HSA (data not shown).
3.3. Anti-microbial activity of SLPI
In a separate set of experiments, the activity of SLPI
against PAO1 and C1705 was tested over the dose range 1^
10 WM and compared with that of full-length ela¢n (Table 1).
The anti-microbial activity of ela¢n against PAO1 conformed
to the characteristic pattern shown in Fig. 2, with a maximal
e¡ect at 2.5 WM. The anti-microbial activity of ela¢n was
greater than that of SLPI at all doses tested. To test for
potential synergy, equimolar concentrations of SLPI and ela-
¢n (0.5 WM ela¢n added to 0.5 WM SLPI) were compared with
either 1 WM ela¢n or 1 WM SLPI alone. No evidence of a
synergistic e¡ect was found (86% killing of PAO1 using the
ela¢n/SLPI combination, 88% using ela¢n alone, 80% using
SLPI alone). The anti-microbial activity of ela¢n and SLPI
against C1705 was similar over the dose range tested.
4. Discussion
Ela¢n (ESI/SKALP) was originally characterised and se-
quenced from human bronchial secretions and from human
psoriatic skin, on the basis of its anti-elastase activity [9,14].
The identi¢cation of anti-microbial activity against Gram-neg-
ative and Gram-positive respiratory pathogens at concentra-
tions potentially achievable in epithelial lining £uid [28] (espe-
cially after genetic augmentation [26]) suggests more complex
functions for ela¢n in the context of in£ammation. This ob-
servation is in keeping with the identi¢cation of additional
functions for other major anti-elastases such as SLPI, which
has intrinsic anti-bacterial and anti-viral activity [5,16,29] and
which can in£uence the function of lipopolysaccharide (LPS)
[30] and prostaglandins [31].
Indeed, ela¢n can be added to the growing list of endoge-
nous lung peptides which harbour an anti-microbial function,
including defensins, SLPI, lactoferrin and lysozyme [1^6].
These molecules share certain general characteristics, for ex-
ample, a low molecular weight and net positive charge. How-
ever, each has unique structural features, which may play a
role in determining the anti-microbial function. The gene se-
quence and derived amino acid sequence of ela¢n have al-
lowed identi¢cation of various structural determinants [13].
The NH2-terminal domain, as de¢ned in this study, has a
net positive charge of +5, as well as repeated structural motifs
potentially acting as substrate for transglutaminase which
may allow ela¢n to bind to the interstitium covalently
[13,15,32]. The COOH-terminal domain, as de¢ned in this
study, has a net positive charge of +2 and has four disul¢de
bonds which confer structural stability [13,32]. Previous stud-
ies using ela¢n fragments of either 57 amino acids (H2N-
Fig. 3. Anti-microbial e¡ect of full-length ela¢n against P. aerugino-
sa (PAO1) and S. aureus (C1705), expressed as a percentage of the
colony count in HSA. In (a), results represent medians (n = 8 for
concentrations of 2.5^25 WM; n = 4 at 1 WM). In (b), results repre-
sent means (n = 5). Comparisons were made between equimolar con-
centrations of test peptide and HSA. * = P6 0.05, ** = P6 0.01,
*** = P6 0.001. For reasons of visual clarity, only data for full-
length ela¢n are shown, however, dose-response curves for NH2-ter-
minal domain ela¢n and COOH-terminal domain ela¢n also closely
paralleled those shown in Fig. 2.
Table 1
Anti-microbial e¡ect of full-length ela¢n and SLPI against P. aeru-
ginosa (PAO1) and S. aureus (C1705)
PAO1 1 WM 2.5 WM 10 WM
Full-length ela¢n 95.7 96.3 85.1
SLPI 93.8 94.7 73.1
C1705
Full-length ela¢n 39.8 37.9 13.6
SLPI 38.1 18.1 6.0
Results are expressed as percentage killing relative to that in PO4
bu¡er alone (taken as 0%) and represent medians from three sepa-
rate experiments.
When expressed relative to HSA, the results obtained were similar
and followed the same trend (data not shown).
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39AQE.....95Q-OH) or 48 amino acids (H2N-48STK.....95Q-
OH) have demonstrated high a⁄nity anti-elastase activity
(Ki in the nM range), but were unable to provide information
concerning the NH2-terminal end of the molecule [9,14,33].
These ¢ndings, in conjunction with crystallographic studies
[17], suggested that ela¢n’s anti-elastase activity resides exclu-
sively in the COOH-terminal domain. Using discrete function-
al domains of ela¢n and studying full-length ela¢n for the ¢rst
time, we have been able to provide direct con¢rmatory evi-
dence to support this hypothesis by demonstrating that the
COOH-terminal domain of ela¢n and the full-length molecule
bind HNE with an equal e⁄ciency (Fig. 1).
Furthermore, the use of discrete functional domains of ela-
¢n has allowed us to infer which regions of the molecule may
be responsible for anti-microbial e¡ects. In the case of P.
aeruginosa, our data suggest that inherent anti-microbial ac-
tivity exists in both structural domains and imply that their
interaction may be necessary to augment anti-microbial activ-
ity at low concentrations. The inverse dose-response relation-
ship noted may re£ect the ability of P. aeruginosa to use high-
er concentrations of peptide as nutrients, promoting growth
and competing with the killing e¡ect of ela¢n. Indeed, P.
aeruginosa is known to grow in increasing concentrations of
organic nitrogen [34]. This may explain why ela¢n’s anti-mi-
crobial e¡ect was slightly less pronounced when albumin was
used as control (see Fig. 3).
The anti-microbial e¡ects of several low molecular weight
peptides have been ascribed to their cationic nature. Cationic
peptides are capable of binding P. aeruginosa LPS, altering
the outer membrane stability and increasing susceptibility to
other bactericidal compounds [35]. While the charge may have
contributed to the killing observed here, it is unlikely to ex-
plain the entire anti-microbial e¡ect of ela¢n (especially at low
doses, where the less cationic COOH-terminal domain was
more e¡ective).
The anti-microbial activity against P. aeruginosa was inde-
pendent of the anti-elastase activity of ela¢n, as the majority
of anti-microbial activity resided in the NH2-terminal domain,
while anti-elastase activity resided exclusively in the COOH-
terminal domain. Interestingly, a quite di¡erent, dose-depend-
ent pattern of anti-microbial activity was seen against S. au-
reus. The NH2-terminal domain alone contributed only
slightly and at high concentrations. As with P. aeruginosa,
this suggests that a simple charge e¡ect is unlikely to explain
ela¢n’s anti-microbial e¡ect. The observation that full-length
ela¢n was more e¡ective than the additive e¡ects of the two
structural domains may again imply a critical interaction
between these. In a similar study using structural domains
derived from SLPI, Hiemstra et al. [5] also found that the
full-length molecule was more active against Escherichia coli
and S. aureus than was either terminal fragment.
In our hands, SLPI was found to have anti-microbial ac-
tivity against P. aeruginosa and S. aureus as has been de-
scribed elsewhere [5,16]. The anti-microbial e¡ects of SLPI
were less pronounced in our study, but this may re£ect the
use of di¡erent clinical strains. Our data suggest that in equi-
molar concentrations, ela¢n is at least as e¡ective as SLPI
against PAO1.
The anti-microbial activity of ela¢n adds to the emerging
picture of its primary role in the lung defence. Ela¢n is ideally
placed to promote the early eradication of invading pathogens
and to protect the host against proteolytic destruction in the
event of neutrophil recruitment. Indeed, the co-existence of
anti-microbial and anti-elastase activity in the ela¢n molecule
could have therapeutic implications. P. aeruginosa and S. au-
reus can each cause severe pneumonia [18,21] and frequently
co-colonise patients with cystic ¢brosis (CF) [19]. The signi¢-
cant morbidity and mortality associated with these organisms,
coupled with their propensity to develop resistance to conven-
tional antibiotics [22,23], demands the development of novel
anti-microbial strategies. In CF, HNE is thought to contribute
to the airway pathology by degrading substrate in the inter-
stitium, enhancing in£ammatory cell chemotaxis, stimulating
mucous hypersecretion and promoting the adherence of P.
aeruginosa [36^38]. Furthermore, PAO1 is known to promote
signi¢cant release of elastase from hamster neutrophils in vivo
[39]. E¡ective augmentation of anti-microbial anti-elastases
for patients known to be at risk of developing infection
with P. aeruginosa and/or S. aureus may thus be theoretically
desirable. Our ¢ndings suggest that ela¢n gene augmentation
could be particularly bene¢cial in CF. Ela¢n levels are known
to be reduced in CF [40], high levels of ela¢n can be e¡ected
using adenoviral gene therapy in rats in vivo [26], ela¢n’s
transglutamination sites may confer a longer biological half-
life in vivo [15,32] and ela¢n appears particularly active
against the non-mucoid clinical isolate PAO1. Strategically,
eradication of P. aeruginosa whilst still in the non-mucoid
form may be especially important in preventing or delaying
progression to chronic infection with mucoid variants, which
are seldom eradicated and are associated with a signi¢cantly
worse prognosis in CF [20].
We recently showed that genetic augmentation of ela¢n
using adenoviral gene therapy protects human alveolar epithe-
lial (A549) cells against HNE and activated neutrophils [41].
We have extended these ¢ndings to show that ela¢n’s anti-
microbial activity against PAO1 can be augmented in super-
natant derived from A549 cells transfected with adenovirus
encoding ela¢n (unpublished data). This suggests that genetic
augmentation of endogenous anti-microbials may be e¡ective
against pulmonary pathogens, as has also been demonstrated
using Q-interferon [42,43].
In summary, these ¢ndings demonstrate for the ¢rst time
that ela¢n has an intrinsic anti-microbial activity against im-
portant Gram-negative and Gram-positive respiratory patho-
gens and that this activity is independent of the molecule’s
anti-elastase activity.
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